



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299 THAMBU CHETTY STREET, CHENNAI - 600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com CIN: L24294
TN1995PLCO30698

9TH May 2022

Listing Department BSE Limited P J Towers, Dalal Street, Mumbai – 400 001 SCRIP CODE: 532989 SCRIP SYMBOL: BAFNAPHARM	Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai – 400051 SCRIP SYMBOL: BAFNAPH
---	--

Dear Sir/Madam,

Sub: Annual disclosure – Non applicability of large corporate entity criteria for the year ended on March 31st 2022 as per SEBI circular No: SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018

We hereby confirm that our Company does not fall under the category "Large Corporate (LC)", as per the framework provided under the said circular.

Please find attached the Annexure B2 as per SEBI circular.

Request you to take the same on record.

Thanking you
Yours faithfully,

For Bafna Pharmaceuticals Limited

RAVIKUMA
R ROOPA
Digitally signed by
RAVIKUMAR ROOPA
Date: 2022.05.09
17:35:16 +05'30'



Roopa Ravi Kumar
Company Secretary & Compliance officer



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, email: info@bafnapharma.com, Website, www.bafnapharma.com
CIN : L24294 TN1995PLC030698

Annexure B2

Format of the Annual Disclosure to be made by an entity identified as a LC^{\$}
(To be submitted to the Stock Exchange(s) within 45 days of the end of the FY)
(Applicable from FY 2022 onwards)

1. Name of the Company: BAFNA PHARMACEUTICALS LIMITED
2. CIN: L24294TN1995PLC030698
3. Report filed for FY: 1st April 2021 – 31st March 2022
4. Details of the Current block (all figures in Rs crore): 4.27

S.No.	Particulars	Details
i.	2-year block period (Specify financial years)	2021-2022 , 2022- 2023
ii.	Incremental borrowing done in FY (T) (a)	1.27 crores in Rs.
iii.	Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)	0
iv.	Actual borrowing done through debt securities in FY (T) (c)	0
v.	Shortfall in the borrowing through debt securities, if any, for FY (T-1) carried forward to FY (T). (d)	0
vi.	Quantum of (d), which has been met from (c) (e)	0
vii.	Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) {after adjusting for any shortfall in borrowing for FY (T-1) which was carried forward to FY (T)} (f)= (b)-[(c)-(e)] {If the calculated value is zero or negative, write "nil"}	0

5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore):

S. No.	Particulars	Details
i.	2-year Block period (Specify financial years)	(T-1) ,(T)




BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, email: info@bafnapharma.com, Website, www.bafnapharma.com
CIN : L24294 TN1995PLC030698

ii.	Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d)-(e)}#	NIL
-----	--	-----


Roopa R

Company Secretary & Compliance officer
9962999335



M. Sridhar
Chief Financial Officer
9551288338

Date 09.05.2022

